Evidence map›Paper›PMID 42728088›Full record

ArticleBMJ open ophthalmology2026

Significance of adjuvant external beam radiotherapy of the orbit in managing uveal melanoma with extraocular extension.

Nathalie Christina Düsberg, Norbert Bornfeld, Anja Merkel-Jens, Philipp Rating, Michael Zeschnigk, Wolfgang A C Sauerwein, Martin Stuschke, Maja Guberina, Nikolaos E Bechrakis, Eva Biewald

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nathalie Christina DüsbergDepartment of Ophthalmology, University Hospital, University of Duisburg-Essen, Essen, Germany N.C.Duesberg@web.de.ORCID http://orcid.org/0009-0007-5700-2217
Norbert BornfeldDepartment of Ophthalmology, University Hospital, University of Duisburg-Essen, Essen, Germany.
Anja Merkel-JensCentre of Clinical Epidemiology, Institute of Medical Informatics, Biometrics and Epidemiology, University Hospital Essen, Essen, Germany.
Philipp RatingDepartment of Ophthalmology, University Hospital, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0003-3621-9007
Michael ZeschnigkInstitute for Human Genetics, Faculty of Medicine, University of Duisburg Essen, Essen, Germany.
Wolfgang A C SauerweinDepartment of Radiation Oncology, University Medicine Essen, Essen, Germany.
Martin StuschkeRadiotherapy, Universitätsklinikum Essen, Essen, Germany.
Maja GuberinaRadiotherapy, Universitätsklinikum Essen, Essen, Germany.
Nikolaos E BechrakisDepartment of Ophthalmology, University Hospital, University of Duisburg-Essen, Essen, Germany.
Eva BiewaldDepartment of Ophthalmology, University Hospital, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-5941-1686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveExtraocular extension (EOE) is a known risk factor for metastasis in uveal melanoma. This long-term study investigates neoadjuvant and adjuvant external beam radiotherapy (EBRT) before and after enucleation of eyes with uveal melanoma and EOE with respect to survival, local tumour control, metastatic disease and side effects of radiotherapy. METHODS AND ANALYSIS: Retrospective, consecutive analysis of all patients with enucleation for uveal melanoma and histopathological evidence of EOE from June 1980 to April 2014.

resultsThe entire cohort comprised 87 patients. 34 of those were lost to follow-up. Of the remaining 43 patients, 26 underwent adjuvant and/or neoadjuvant radiotherapy with a total orbital dose of 50-60 Gy, while the remaining 17 were treated with enucleation only. The mean follow-up time was 65.58±80.44 months (median 37 months) and 184.12±119.760 months (median 132 months) for those being alive at last follow-up. EBRT patients had significantly higher TNM (tumour, node, metastases) stages (p=0.033) and more extensive EOE (p=0.146). There was no significant difference in any relevant parameters between the two groups. The overall survival rate after 5 and 10 years was 32.6% and 16.2%, respectively. There was no evidence of a significantly later (p=0.573) or less frequent (p=0.999) occurrence of metastases in either group. There were no local recurrences in either group. Side effects of the radiotherapy occurred in 61.5%.

conclusionsAdjuvant or neoadjuvant EBRT had no survival benefit in uveal melanoma with EOE. No local recurrence was detected in either group.

Indexed as

MelanomaOrbitOrbital NeoplasmsUveal NeoplasmsAdultAgedAged, 80 and overEye EnucleationFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingRadiotherapy, AdjuvantRadiotherapy DosageChoroidClinical TrialNeoplasiaTreatment Medical

Identifiers

PMID42728088
PMCPMC13583686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.